NEW YORK, March 16 (GenomeWeb News) - DiaGenic, a Norwegian in vitro diagnostics company that has been developing a test for early breast cancer based on microarray platforms, said last week that it is looking for a chip vendor to help it develop and eventually launch the product.
The publicly held company said it initially developed the test with macroarrays, but through research learned that it works on Agilent's microarray platform, and may work with other commercial microarrays as well.
DiaGenic is now testing the capabilities of the diagnostic by using a variety of commercial platforms at the Norwegian Radium Hospital. The firm said that the fact the test works with commercial chips broadens the field of possible collaborators for the scheduled 2006 launch of its test.
DiaGenic said that it can develop the test on schedule with a budget of NOK 10 million ($1.6 million), and that it was looking to partner with a platform provider within the first half of 2005.
Christina Maehr, a spokesperson for Agilent, said that she could not comment on whether Agilent was involved in discussions with Diagenic, but said they are interested in partnering for these kinds of diagnostic tests. "We are already in discussion with some parties about possible diagnostic opportunities and we are absolutely interested in having more of those discussions," Maehr said.